Skip to main content
. Author manuscript; available in PMC: 2010 Apr 14.
Published in final edited form as: J Am Coll Cardiol. 2009 Apr 14;53(15):1273–1278. doi: 10.1016/j.jacc.2008.12.044

Figure 1. Benefit of Clopidogrel on Primary Endpoint by Smoking Status.

Figure 1

The primary efficacy endpoint was a composite of Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 or 1 on angiography or death or recurrent myocardial infarction prior to angiography. Odds ratios (OR) are adjusted for age, sex, region, hypertension, diabetes, infarct location, time to fibrinolytic therapy, and type of fibrinolytic. For each subgroup, the size of the box is proportional to the number of individuals included in the analysis. The horizontal lines represent the 95 percent confidence intervals (CI).